Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for chronic inflammation associated with ...

A recent structured review sheds light on the potential benefits of tumor necrosis factor inhibitors (TNFis) in addressing this concern. The review highlights that TNF plays a pathological role in ...

Objective To quantify comparative effectiveness of interleukin (IL)−12/23 antagonist (ustekinumab), IL-17A antagonists (secukinumab and ixekizumab), PDE4 inhibitor (apremilast) and tumour necrosis ...

At 12 months, 25.1% of patients starting tofacitinib and 30.1% of TNF inhibitor initiators achieved low disease activity. Tofacitinib demonstrated similar effectiveness to tumor necrosis factor (TNF) ...